Loading data for XLO — first visit, this takes a few seconds.

알림

Xilio Therapeutics Inc. (XLO)

NasdaqCM: XLO · 실시간 가격 · USD

9.41

-0.09 (-0.95%)

종가 기준: Aug 19, 2026, 3:57 PM

-0.95% (1D)

매수호가	6.75
시가총액	60.21M
매출 (ttm)	64.09M
순이익 (ttm)	-21.83M
베타	-0.12
EPS (ttm)	-0.32
P/E (ttm)	n/a
선행 P/E	-15.78
P/B (ttm)	1.18
P/S (ttm)	0.94
Earnings Date	n/a

매도호가	12.16
거래량	6,586
평균 거래량 (20일)	34,574
시가	9.12
전일 종가	9.50
일중 범위	9.12 - 9.48
52주 범위	6.47 - 12.74
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

XLO 소개

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 22, 2021

직원 수 76

상장 거래소 NasdaqCM

티커 XLO

웹사이트 https://xiliotx.com

전체 기업 정보

재무 실적

2025년 Xilio Therapeutics의 매출은 43.77M로, 전년 6.34M 대비 589.88% 증가했습니다. 순이익은 -35.04M로, -39.84% 감소했습니다.

재무제표

어닝 서프라이즈

Xilio Therapeutics가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $12.65M 예상치 하회 $0, 및 331.67% 전년 대비 성장.

EPS -0.33 예상치 상회 0.26, 및 88.21% 전년 대비 성장.

뉴스

3주 전 · Simply Wall St.

3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership

Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.

3개월 전 · Zacks

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of +12.12% and +48.45%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3개월 전 · Zacks

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

3개월 전 · Zacks

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Oculis Holding AG (OCS) delivered earnings and revenue surprises of -27.71% and -17.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

4개월 전 · Zacks

Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?

Xilio Therapeutics (XLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 페이지 중 1

Xilio Therapeutics Inc. (XLO)